Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 433-448

  Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BCR ABL mutations; CML; Drug resistance; Imatinib; Stem cells

Indexed keywords

EID: 77949767699     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (180)

1. Abruzzese E, Cantonetti M, Morino L, et al. 2003. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. J Clin Oncol, 21:4256-8.
2. Abdelhalim A, Barcos M, Block AW, et al. 2007. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leuk Lymphoma, 48:1053-6.
3. Agis H, Mannhalter C, Sperr WR, et al. 2004. Detection of trisomy 8 in donor-derived Phcells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. Leuk Lymphoma, 45:1453-8.
4. Angstreich GR, Matsui W, Huff CA, et al. 2005. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol, 130:373-81.
5. Aichberger KJ, Herndlhofer S, Agis H, et al. 2007. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukemia occurring during imatinib therapy. Eur J Clin Invest, 37:808-13.
6. Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell, 112:831-43.
7. Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108:1809-20.
8. Barbany G, Hoglund M, Simonsson B; Swedish CML Group. 2002. Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med, 347:539-40.
9. Barnes DJ, Melo JV. 2006. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle, 5:2862-6.
10. Barthe C, Gharbi MJ, Lagarde V, et al. 2002. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br J Haematol, 119:109-11.
11. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101:4701-7.
12. Biernaux C, Loos M, Sels A, et al. 1995. Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood, 86:3118-22.
13. Bolton AE, Peng B, Hubert M, et al. 2004. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol, 53:102-6.
14. Bornhäuser M, Jenke A, Freiberg-Richter J, et al. 2004. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol, 83:401-2.
15. Bose S, Deininger M, Gora-Tybor J, et al. 1998. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood, 92:3362-7.
16. Branford S, Rudzki Z, Walsh S, et al. 2002. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99:3472-5.
17. Branford S, Rudzki Z, Walsh S, et al. 2003. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, 102:276-83.
18. Breedveld P, Beijnen JH, Schellens JH. 2006. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci, 27:17-24.
19. Breedveld P, Pluim D, Cipriani G, et al. 2005. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res, 65:2577-82.
20. Breccia M, Diverio D, Pane F, et al. 2006. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res, 30:1577-9.
21. Brendel C, Scharenberg C, Dohse M, et al. 2007. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia, 2007; 21:1267-75.
22. Burger H, Nooter K. 2004. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle, 3:1502-5.
23. Burger H, van Tol H, Brok M, et al. 2005. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther, 4:747-52.
24. Calabretta B, Perrotti D. 2004. The biology of CML blast crisis. Blood, 103:4010-22.
25. Campbell LJ, Patsouris C, Rayeroux KC, et al. 2002. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet, 139:30-3.
26. Carter TA, Wodicka LM, Shah NP, et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA, 102:11011-6.
27. Cheetham GM, Charlton PA, Golec JM, et al. 2007. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett, 251:323-9.
28. Cohen MH, Williams G, Johnson JR, et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 8:935-42.
29. Copland M, Hamilton A, Elrick LJ, et al. 2006. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107:4532-9.
30. Copland M, Jorgensen HG, Holyoake TL. 2005. Evolving molecular therapy for chronic myeloid leukaemia are we on target? Hematology, 10:349-59.
31. Cortes J, Kantarjian H. 2003. Advanced-phase chronic myeloid leukemia. Semin Hematol, 40:79-86.
32. Cortes JE, Talpaz M, Giles F, et al. 2003. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 101:3794-800.
33. Cortes J, Rousselot P, Kim DW, et al. 2007. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109:3207-13.
34. Cortes JE, Talpaz M, O'Brien S, et al. 2006. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer, 106:1306-15.
35. Cowan-Jacob SW, Guez V, Fendrich G, et al. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem, 4:285-99.
36. Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247:824-30.
37. de Klein A, van Kessel AG, Grosveld G, et al. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature, 300:765-7.
38. Dai H, Marbach P, Lemaire M, et al. 2003. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther, 304:1085-92.
39. Deininger MW. 2007. Optimizing therapy of chronic myeloid leukemia. Exp Hematol, 35(S1):144-54.
40. Devireddy LR, Gazin C, Zhu X, Green MR. 2005. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell, 123:1293-305.
41. Diaz-Blanco E, Bruns I, Neumann F, et al. 2007. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia, 21:494-504.
42. Druker BJ, Guilhot F, O'Brien SG, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355:2408-17.
43. Druker BJ, Sawyers CL, Kantarjian H, et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 344:1038-42.
44. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344:1031-7.
45. Dutcher JP, Wiernik PH. 2000. Accelerated and blastic phase of chronic myeloid leukemia. Curr Treat Options Oncol, 1:51-62.
46. Dutreix C, Peng B, Mehring G, et al. 2004. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol, 54:290-4.
47. Eaves AC, Barnett MJ, Ponchio L, et al. 1998. Cashman JD, Petzer AL, Eaves CJ. Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells, 16(S1):77-83.
48. Eaves C, Udomsakdi C, Cashman J, et al. 1993. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma, 11S1:245-53.
49. Eckel F, von Delius S, Mayr M, et al. 2005. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology, 69:363-71.
50. Eisterer W, Jiang X, Christ O, et al. 2005. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia, 19:435-41.
51. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. 2005. Punish the parent not the progeny. Blood, 105:1862-6.
52. Frye RF, Fitzgerald SM, Lagattuta TF, et al. 2004. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther, 76:323-9.
53. Gadzicki D, von Neuhoff N, Steinemann D, et al. 2005. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet, 159:164-7.
54. Gargallo PM, Cuello MT, Aranguren PN, et al. 2003. Amplification of the BCR/ABL fusion gene clustered on a masked Philadelphia chromosome in a patient with myeloblastic crisis of chronic myelocytic leukemia. Cancer Genet Cytogenet, 143:140-4.
55. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. 2004. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am, 18:753-74.
56. Giles FJ, Cortes J, Jones D, et al. 2007. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 109:500-2.
57. Giralt SA, Arora M, Goldman JM, et al. 2007. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol, 137:461-7
58. Gishizky ML, Witte ON. 1992. Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science, 256:836-9.
59. Goldman J, Gordon M. 2006. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma, 47:1-7.
60. Goldman JM, Apperley JF, Jones L, et al. 1986. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med, 314:202-7.
61. Gorre ME, Mohammed M, Ellwood K, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293:876-80.
62. Graham SM, Jorgensen HG, Allan E, et al. 2002. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99:319-25.
63. Gratwohl A, Hermans J, Goldman JM, et al. 1998. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352:1087-92.
64. Griswold IJ, MacPartlin M, Bumm T, et al. 2006. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol, 26:6082-93.
65. Gschwind HP, Pfaar U, Waldmeier F, et al. 2005. Pokorny R, Seiberling M, Ben-Am M, Peng B, Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos, 33:1503-12.
66. Guilhot F, Apperley J, Kim DW, et al. 2007. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinibresistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 109:4143-50.
67. Gumireddy K, Baker SJ, Cosenza SC, et al. 2005. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA, 102:1992-7.
68. Herweijer H, Sonneveld P, Baas F, Nooter K. 1990. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst, 82:1133-40.
69. Hochhaus A, Erben P, Ernst T, Mueller MC. 2007. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol, 44: S15-24.
70. Hochhaus A, Kantarjian HM, Baccarani M, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood, 109:2303-9.
71. Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16:2190-6.
72. Holyoake TL, Horrocks C, Thomas T, et al. 2000. Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID mice. Cytotherapy, 2:411-21.
73. Holyoake TL, Jiang X, Drummond MW, et al. 2002. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia, 16:549-58.
74. Holyoake TL, Jiang X, Jorgensen HG, et al. 2001. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97:720-8.
75. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. 2001. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene, 20:5826-35.
76. Hughes TP, Kaeda J, Branford S, et al. 2003. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med, 349:1423-32.
77. Illmer T, Schaich M, Platzbecker U, et al. 2004. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia, 18:401-8.
78. Jabbour E, Cortes J, Kantarjian HM, et al. 2006. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood, 108:1421-3.
79. Jabbour E, Cortes J, Kantarjian H, et al. 2007. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer, 110:340-44.
80. Jabbour E, Cortes J, O'Brien S, et al. 2007. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol, 44(S1):S25-31.
81. Jabbour E, Kantarjian HM, Abruzzo L, et al. 2007. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood, in press.
82. Jabbour E, Kantarjian H, Jones D, et al. 2006. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia, 20:1767-73.
83. Jiang X, Saw KM, Eaves A, Eaves C. 2007. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst, 99:680-93.
84. Jiang X, Zhao Y, Smith C, et al. 2007. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia, 21:926-35.
85. Kantarjian HM, Cortes J, O'Brien S, et al. 2002. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 99:3547-53.
86. Kantarjian H, Giles F, Wunderle L, et al. 2006. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 354:2542-51.
87. Kantarjian H, Sawyers C, Hochhaus A, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346:645-52.
88. Kantarjian HM, Talpaz M, Giles F, et al. 2006. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med, 145:913-23.
89. Kantarjian HM, Talpaz M, O'Brien S, et al. 2003. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101:473-5.
90. Khorashad JS, Anand M, Marin D, et al. 2006. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia, 20:658-63.
91. Kim HJ, Jung CW, Kim K, et al. 2006. Isolated blast crisis in CNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinib. J Clin Oncol, 24:4028-29.
92. Kimura S, Naito H, Segawa H, et al. 2005. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinibresistant leukemia. Blood, 106:3948-54.
93. Kreuzer KA, Le Coutre P, Landt O, et al. 2003. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol, 82:284-9.
94. le Coutre P, Kreuzer KA, Pursche S, et al. 2004. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol, 53:313-23.
95. le Coutre P, Tassi E, Varella-Garcia M, et al. 2000. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95:1758-66.
96. Leis JF, Stepan DE, Curtin PT, et al. 2004. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma, 45:695-8.
97. Li Z, Qiao Y, Liu B, et al. 2005. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res, 11:4460-8.
98. Lin H, Monaco G, Sun T, et al. 2005. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia. Oncogene, 24:3246-56.
99. Lin Y, Bruyere H, Horsman DE, et al. 2006. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet, 170:16-23.
100. Loriaux M, Deininger M. 2004. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma, 45:2197-203.
101. Lugo TG, Pendergast AM, Muller AJ, Witte ON. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247:1079-82.
102. Mahon FX, Belloc F, Lagarde V, et al. 2003. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood, 101:2368-73.
103. Marktel S, Marin D, Foot N, et al. 2003. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 88:260-7.
104. Martinelli G, Soverini S, Rosti G, et al. 2005. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica, 90:534-41.
105. Matsuda M, Morita Y, Shimada T, et al. 2005. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol, 81:307-9.
106. Medina J, Kantarjian H, Talpaz M, et al. 2003. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase. Cancer, 98:1905-11.
107. Melo JV, Barnes DJ. 2007. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer, 7:441-53.
108. Melo JV, Deininger MW. 2004. Biology of chronic myelogenous leukemia signaling pathways of initiation and transformation. Hematol Oncol Clin North Am, 18:545-68.
109. Menzel H, von Bubnoff N, Hochhaus A, et al. 2007. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant, 40:83-4.
110. Michor F, Hughes TP, Iwasa Y, et al. 2005. Dynamics of chronic myeloid leukaemia. Nature, 435:1267-70.
111. Morel F, Bris MJ, Herry A, et al. 2003. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol, 70:235-9.
112. Navarro JT, Feliu E, Grau J, et al. 2007. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. Am J Hematol, 82:849-51.
113. Neviani P, Santhanam R, Trotta R, et al. 2006. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 5:355-68.
114. Nguyen Khac F, Waill MC, Romana SP, et al. 2002. Identical abnormality of the short arm of chromosome 18 in two Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic transformation, resulting in duplication of BCR-ABL1 fusion. Cancer Genet Cytogenet, 138:22-6.
115. Nicolini FE, Corm S, Le QH, et al. 2006. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia, 20:1061-6.
116. Nowell PC, Hungerford DA. 1960. A minute chromosome in human granulocytic leukemia. Science, 132:1497.
117. O'Brien SG, Guilhot F, Larson RA, et al. 2003. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348:994-1004.
118. O'Brien SG, Meinhardt P, Bond E, et al. 2003. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer, 89:1855-9.
119. O'Dwyer ME, Mauro MJ, Blasdel C, et al. 2004. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood, 103:451-5.
120. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, CowanJacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65:4500-5.
121. Pappas P, Karavasilis V, Briasoulis E, et al. 2005. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemother Pharmacol, 56:358-60.
122. Pavlu J, Czepulkowski B, Kaczmarski R, Jan-Mohamed R. 2005. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. Lancet Oncol, 6:128.
123. Pendergast AM, Quilliam LA, Cripe LD, et al. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75:175-85.
124. Peng B, Dutreix C, Mehring G, et al. 2004. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol, 44:158-62.
125. Peng B, Hayes M, Resta D, et al. 2004. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol, 22:935-42.
126. Peng C, Brain J, Hu Y, et al. 2007. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood, 110:678-85.
127. Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet, 44:879-94.
128. Picard S, Titier K, Etienne G, et al. 2007. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood, 109:3496-9.
129. Pienkowska-Grela B, Woroniecka R, Solarska I, et al. 2007. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet, 174:111-5.
130. Puil L, Liu J, Gish G, et al. 1994. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J, 13:764-73.
131. Quintas-Cardama A, Kantarjian H, Jones D, et al. 2007. Dasatinib (BMS354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 109:497-9.
132. Radich JP, Dai H, Mao M, et al. 2006. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA, 103:2794-9.
133. Rahmani M, Nguyen TK, Dent P, et al. 2007. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant BCR/ABL+ human leukemia cells in association with STAT5 inhibition and MCL-1 downregulation. Mol Pharmacol, 72:788-95.
134. Rajappa S, Uppin SG, Raghunadharao D, et al. 2004. Isolated central nervous system blast crisis in chronic myeloid leukaemia. Hematol Oncol, 22:179-81.
135. Ren R. 2005. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer, 5:172-83.
136. Roche-Lestienne C, Preudhomme C. 2003. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol, 40(S2):80-2.
137. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. 2002. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100:1014-8.
138. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. 2006. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med, 12:1181-4.
139. Roumiantsev S, Shah NP, Gorre ME, et al. 2002. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA, 99:10700-5.
140. Rousselot P, Huguet F, Rea D, et al. 2007. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood, 109:58-60.
141. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243:290-3.
142. Rytting ME, Wierda WG. 2004. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma, 45:1623-6.
143. Sattler M, Griffin JD. 2003. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol, 40:4-10.
144. Sawyers CL, Hochhaus A, Feldman E, et al. 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99:3530-9.
145. Senior K. 2003. Gleevec does not cross blood-brain barrier. Lancet Oncol, 4:198.
146. Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2:117-25.
147. Shah NP, Tran C, Lee FY, et al. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305:399-401.
148. Shet AS, Jahagirdar BN, Verfaillie CM. 2002. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia, 16:1402-11.
149. Silberman G, Crosse MG, Peterson EA, et al. 1994. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med, 331:1063-7.
150. Sillaber C, Gesbert F, Frank DA, et al. 2000. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood, 95:2118-25.
151. Skaggs BJ, Gorre ME, Ryvkin A, et al. 2006. Phosphorylation of the ATPbinding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA, 103:19466-71.
152. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J, 16:6151-61.
153. Soverini S, Martinelli G, Rosti G, et al. 2005. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol, 23:4100-9.
154. Takayama N, Sato N, O'Brien SG, et al. 2002. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 119:106-8.
155. Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354:2531-41.
156. Talpaz M, Silver RT, Druker BJ, et al. 2002. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99:1928-37.
157. Tanaka K, Arif M, Kyo T, et al. 2000. Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes. Cancer Genet Cytogenet, 119:8-14.
158. Tauchi T, Ohyashiki K. 2006. The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol, 83:294-300.
159. Terre C, Eclache V, Rousselot P, et al. 2004. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia, 18:1340-6.
160. Thomas J, Wang L, Clark RE, Pirmohamed M. 2004. Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104:3739-45.
161. Tseng PH, Lin HP, Zhu J, et al. 2005. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood, 105:4021-7.
162. Van Etten RA. 2007. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med, 204:461-5.
163. Verbeek W, Konig H, Boehm J, et al. 2006. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Acta Haematol, 115:109-12.
164. Villuendas R, Steegmann JL, Pollan M, et al. 2006. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia, 20:1047-54.
165. Volpe G, Cignetti A, Panuzzo C, et al. 2007. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res, 67:5300-7.
166. von Bubnoff N, Schneller F, Peschel C, et al. 2002. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukaemia to STI571: a prospective study. Lancet, 359:487-91.
167. Wang L, Giannoudis A, Lane S, et al. 2007. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther, doi:10.1038/sj.clpt.6100268.
168. Weisberg E, Manley PW, Breitenstein W, et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7:129-41.
169. Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765-9.
170. Weisberg E, Catley L, Wright RD, et al. 2007. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood, 109:2112-20.
171. Weisberg E, Griffin JD. 2000. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 95:3498-505.
172. Weisberg E, Manley PW, Cowan-Jacob SW, et al. 2007. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer, 7:345-56.
173. Weisser M, Schleuning M, Haferlach C, et al. 2007. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma, 48:295-301.
174. Westermann J, Kopp J, van Lessen A, et al. 2007. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol, 137:297-306.
175. Wetzler M, Talpaz M, Van Etten RA, et al. 1993. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest, 92:1925-39.
176. White DL, Saunders VA, Quinn SR, et al. 2007. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood, 109:3609-10.
177. Wild R, Castaneda S, Flefleh C, et al. 2004. BMS-354825, a dual SRC/ABL kinase inhibitor, displays potent anti-tumor activity in a model of intracranial CML growth. Blood, 104:549a.
178. Wolff NC, Richardson JA, Egorin M, Ilaria RL. 2003. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood, 101:5010-3.
179. Yokota A, Kimura S, Masuda S, et al. 2007. INNO-406, a novel BCRABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 109:306-14.
180. Zheng C, Li L, Haak M, et al. 2006. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia, 20:1028-34.